Our prime vaccine candidate has exhibited high immunogenicity and superb neutralization results in preclinical testing. We are actively engaged in mucosal immunogenicity studies with adjuvants that have proven clinical record. This will enable us to proceed to first-in-human trials with minimal efforts and resources.

We have have contacted nationial an EU-level regulatory authorities to enable smooth transition from development and preclinical to clinical studies as soon as the most promising candidate formulations are selected. We are open for collaborations and we are seeking national and international grants.

 

Trying to bring prosperity and equal oportunity to every person in face of climate change, globalization and aging society is a great challenge for us all. To ensure a safe future, it is vital to invest in pandemic preparedness and cancer immunology. Sferogen is set to establish a portfolio of affordable and accessible vaccine candidates for key emerging zoonotic diseases and oncology.